Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333PARA, Michael F; GLIDDEN, David V; BOUCHER, Charles et al.The Journal of infectious diseases. 2000, Vol 182, Num 3, pp 733-743, issn 0022-1899Article

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trialsERON, Joseph J; YOUNG, Benjamin; KUMAR, Princy N et al.Lancet (British edition). 2010, Vol 375, Num 9712, pp 396-407, issn 0140-6736, 12 p.Article

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialLENNOX, Jeffrey L; DEJESUS, Edwin; BARNARD, Richard J. O et al.Lancet (British edition). 2009, Vol 374, Num 9692, pp 796-806, issn 0140-6736, 11 p.Article

Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/ Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients: 156-Week Results From STARTMRKROCKSTROH, Jiirgen K; LENNOX, Jeffrey L; DINUBILE, Mark J et al.Clinical infectious diseases. 2011, Vol 53, Num 8, pp 807-816, issn 1058-4838, 10 p.Article

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialERON, Joseph; ROCKSTROH, Jürgen K; NELSON, Mark et al.Lancet. Infectious diseases (print). 2011, Vol 11, Num 12, pp 907-915, issn 1473-3099, 9 p.Article

Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trialsCOPLAN, Paul M; NIKAS, Alexander A; LEAVITT, Randi Y et al.AIDS (London). 2001, Vol 15, Num 12, pp 1584-1586, issn 0269-9370Article

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesROCKSTROH, Jürgen K; TEPPLER, Hedy; JING ZHAO et al.AIDS (London). 2011, Vol 25, Num 11, pp 1365-1369, issn 0269-9370, 5 p.Article

Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infectionHIRSCH, Martin S; STEIGBIGEL, Roy T; LEAVITT, Randi Y et al.Clinical infectious diseases. 2003, Vol 37, Num 8, pp 1119-1124, issn 1058-4838, 6 p.Article

Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B gag Vaccines in Healthy AdultsHARRO, Clayton D; ROBERTSON, Michael N; XIAO SUN et al.AIDS research and human retroviruses. 2009, Vol 25, Num 1, pp 103-114, issn 0889-2229, 12 p.Article

Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy AdultsPRIDDY, Frances H; BROWN, Deborah; BROWN, Stephen J et al.Clinical infectious diseases. 2008, Vol 46, Num 11, pp 1769-1781, issn 1058-4838, 13 p.Article